

July 2022

## BCBSAL Step Therapy Utilization Management

### Step Therapy

Step therapy program is a “step” approach to providing the medications that treat your condition. This means that you may first need to try a more clinically appropriate or cost-effective medication before certain higher-cost medications will be approved. Step therapy programs can help both you and the health plan save money.

The Step Therapy form that your physician will need to complete to request an approval can be found on the MyPrime website.

Utilization Management Program	Prerequisites	Drug(s) in Program
<b>Antidepressants</b>	<b>Generic bupropion, bupropion ER, citalopram, duloxetine, escitalopram, fluoxetine, fluoxetine DR, fluvoxamine, fluvoxamine ER, mirtazapine, paroxetine, paroxetine ER, sertraline, venlafaxine, venlafaxine ER</b> <b>Additional alternatives for Cymbalta/Drizalma only: amitriptyline, cyclobenzaprine, desipramine, gabapentin, imipramine, nortriptyline, tramadol</b>	APLENZIN
		BUPROPION HYDROCHLORIDE ER (XL)
		CELEXA
		CITALOPRAM HYDROBROMIDE
		CYMBALTA
		DESVENLAFAXINE ER
		DRIZALMA SPRINKLE
		EFFEXOR XR
		FETZIMA
		FETZIMA TITRATION PACK
		FLUOXETINE DR
		FLUOXETINE HYDROCHLORIDE
		FORFIVO XL
		LEXAPRO
		MAPROTILINE HCL
		PAXIL
		PAXIL CR

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner. NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Prerequisites	Drug(s) in Program
		PEXEVA
		PRISTIQ
		PROZAC
		REMERON
		REMERON SOLTAB
		SERTRALINE HYDROCHLORIDE
		TRINTELLIX
		VIIBRYD
		VIIBRYD STARTER PACK
		WELLBUTRIN SR
		WELLBUTRIN XL
		ZOLOFT
<b>Antiemetic Agents</b>	<b>A generic oral 5HT-3 antiemetic agent</b>	SANCUSO
		ZUPLENZ
<b>ARB Renin Inhibitors</b>	<b>A generic ACE Inhibitor or ACE Inhibitor combination (e.g. enalapril, lisinopril, benazepril) A generic ARB or ARB combination (e.g. amlodipine-valsartan/HCTZ, candesartan, eprosartan, irbesartan, losartan, telmisartan, valsartan, telmisartan/amlodipine, telmisartan/HCTZ, valsartan/amlodipine) A generic renin inhibitor or renin inhibitor combination (e.g. aliskiren)</b>	ATACAND
		ATACAND HCT
		AVALIDE
		AVAPRO
		AZOR
		BENICAR
		BENICAR HCT
		COZAAR
		DIOVAN
		DIOVAN HCT
		EDARBI
		EDARBYCLOR
		EXFORGE
		EXFORGE HCT
		HYZAAR
		MICARDIS
		MICARDIS HCT
		TEKTURN
		TEKTURN HCT
		TRIBENZOR

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Prerequisites	Drug(s) in Program
		TWYNSTA
<b>Atopic Dermatitis</b>	<b>A topical corticosteroid or a topical corticosteroid combination preparation</b>	ELIDEL
		EUCRISA
		pimecrolimus
		PROTOPIC
		tacrolimus
<b>Atypical Antipsychotics</b>	<b>A generic atypical antipsychotic Additional alternatives for Abilify only: generic haloperidol, pimozone</b>	ABILIFY
		ABILIFY MYCITE
		ABILIFY MYCITE MAINTENANCE KIT
		ABILIFY MYCITE STARTER KIT
		CAPLYTA
		CLOZAPINE ODT
		CLOZARIL
		FANAPT
		FANAPT TITRATION PACK
		GEODON
		INVEGA
		LYBALVI
		RISPERDAL
		RISPERIDONE ODT
		SAPHRIS
		SECUADO
		SEROQUEL
		SEROQUEL XR
		VERSACLOZ
		VRAYLAR
		ZYPREXA
		ZYPREXA ZYDIS
<b>Atypical Antipsychotics Extended Maintenance</b>	<b>An oral short-acting atypical antipsychotic agent with same active ingredient</b>	ABILIFY MAINTENA
	<b>An oral short-acting atypical antipsychotic agent with same active ingredient</b>	ARISTADA
	<b>An oral short-acting atypical antipsychotic agent with same active ingredient</b>	ARISTADA INITIO
	<b>Invega Sustenna, Invega Trinza</b>	INVEGA HAFYERA
	<b>An oral short-acting atypical antipsychotic agent with same active ingredient</b>	INVEGA SUSTENNA
	<b>Invega Sustenna</b>	INVEGA TRINZA
	<b>An oral short-acting atypical antipsychotic agent with same active ingredient</b>	PERSERIS

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Prerequisites	Drug(s) in Program
	An oral short-acting atypical antipsychotic agent with same active ingredient	RISPERDAL CONSTA
	An oral short-acting atypical antipsychotic agent with same active ingredient	ZYPREXA RELPREVV
Continuous Glucose Monitor	A rapid acting insulin, regular acting insulin	DEXCOM G5 MOBILE RECEIVERKIT
		DEXCOM G5 MOBILE TRANSMITTER KIT
		DEXCOM G5 MOBILE/G4 PLATINUM SENSOR KIT
		DEXCOM G5 RECEIVER KIT
		DEXCOM G6 RECEIVER
		DEXCOM G6 SENSOR
		DEXCOM G6 TRANSMITTER
		FREESTYLE LIBRE 14 DAY/READER/FLASH MONITORING SYSTEM
		FREESTYLE LIBRE 14 DAY/SENSOR/FLASH MONITORING SYSTEM
		FREESTYLE LIBRE 2/READER/FLASH GLUCOSE MONITORING SYSTEM
		FREESTYLE LIBRE 2/SENSOR/FLASH GLUCOSE MONITORING SYSTEM
		FREESTYLE LIBRE/READER/FLASH MONITORING SYSTEM
		FREESTYLE LIBRE/SENSOR/FLASH MONITORING SYSTEM
DPP-4 Inhibitors	Januvia, Janumet, Janumet XR	ALOGLIPTIN
		ALOGLIPTIN/METFORMIN HCL
		ALOGLIPTIN/PIOGLITAZONE
		JENTADUETO
		JENTADUETO XR
		KAZANO
		KOMBIGLYZE XR
		NESINA
		ONGLYZA
		OSENI
		TRADJENTA
GLP-1 Agonists	Generic metformin, a combination product containing metformin, insulin	ADLYXIN
		ADLYXIN STARTER PACK
		BYDUREON BCISE
		BYDUREON PEN

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Prerequisites	Drug(s) in Program
		BYETTA
		OZEMPIC
		RYBELSUS
		TRULICITY
		VICTOZA
<b>Insulin Combinations</b>	<b>Generic metformin, a combination product containing metformin, insulin</b>	SOLIQUA 100/33
		XULTOPHY 100/3.6
<b>Metformin ER</b>	<b>A non-targeted generic metformin ER</b>	FORTAMET
		GLUMETZA
		metformin hydrochloride er
		RIOMET ER
<b>Methotrexate Injectable Agents</b>	<b>Generic methotrexate injectable solution (methotrexate sodium solution)</b>	OTREXUP
	<b>Generic methotrexate injectable solution (methotrexate sodium solution) AND Otrexup AND RediTrex</b>	RASUVO
	<b>Generic methotrexate injectable solution (methotrexate sodium solution)</b>	REDITREX
<b>Multiple Sclerosis</b>	<b>Generic dimethyl fumarate, glatiramer</b>	AUBAGIO
	<b>Generic dimethyl fumarate, glatiramer</b>	AVONEX
	<b>Generic dimethyl fumarate, glatiramer</b>	AVONEX PEN
	<b>ONE of the following: Generic dimethyl fumarate, glatiramer AND ONE of the following: Aubagio, Avonex, Betaseron, Gilenya, Kesimpta, Mavenclad, Mayzent, Plegridy, Rebif, Zeposia</b>	BAFIERTAM
	<b>Generic dimethyl fumarate, glatiramer</b>	BETASERON
	<b>Generic glatiramer AND ONE of the following: Aubagio, Avonex, Betaseron, Gilenya, Kesimpta, Mavenclad, Mayzent, Plegridy, Rebif, Zeposia</b>	COPAXONE
	<b>ONE of the following: Generic dimethyl fumarate, glatiramer AND ONE of the following: Aubagio, Avonex, Betaseron, Gilenya, Kesimpta, Mavenclad, Mayzent, Plegridy, Rebif, Zeposia</b>	EXTAVIA
	<b>Generic dimethyl fumarate, glatiramer</b>	GILENYA
	<b>Generic glatiramer AND</b>	glatopa

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Prerequisites	Drug(s) in Program
	ONE of the following: Aubagio, Avonex, Betaseron, Gilenya, Kesimpta, Mavenclad, Mayzent, Plegridy, Rebif, Zeposia	
	Generic dimethyl fumarate, glatiramer	KESIMPTA
	Generic dimethyl fumarate, glatiramer	MAVENCLAD
	Generic dimethyl fumarate, glatiramer	MAYZENT
	Generic dimethyl fumarate, glatiramer	MAYZENT STARTER PACK
	Generic dimethyl fumarate, glatiramer	PLEGRIDY
	Generic dimethyl fumarate, glatiramer	PLEGRIDY STARTER PACK
	ONE of the following: Generic dimethyl fumarate, glatiramer AND ONE of the following: Aubagio, Avonex, Betaseron, Gilenya, Kesimpta, Mavenclad, Mayzent, Plegridy, Rebif, Zeposia	PONVORY
	ONE of the following: Generic dimethyl fumarate, glatiramer AND ONE of the following: Aubagio, Avonex, Betaseron, Gilenya, Kesimpta, Mavenclad, Mayzent, Plegridy, Rebif, Zeposia	PONVORY 14-DAY STARTER PACK
	Generic dimethyl fumarate, glatiramer	REBIF
	Generic dimethyl fumarate, glatiramer	REBIF REBIDOSE
	Generic dimethyl fumarate, glatiramer	REBIF REBIDOSE TITRATION PACK
	Generic dimethyl fumarate, glatiramer	REBIF TITRATION PACK
	Generic dimethyl fumarate AND ONE of the following: Aubagio, Avonex, Betaseron, Gilenya, Kesimpta, Mavenclad, Mayzent, Plegridy, Rebif, Zeposia	TECFIDERA
	Generic dimethyl fumarate AND ONE of the following: Aubagio, Avonex, Betaseron, Gilenya, Kesimpta, Mavenclad, Mayzent, Plegridy, Rebif, Zeposia	TECFIDERA STARTER PACK
	ONE of the following: Generic dimethyl fumarate, glatiramer AND ONE of the following: Aubagio, Avonex, Betaseron, Gilenya, Kesimpta, Mavenclad, Mayzent, Plegridy, Rebif, Zeposia	VUMERITY
Oral Tetracycline Derivatives	Any one preferred generic doxycycline agent AND Any one preferred generic minocycline agent	ACTICLATE

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Prerequisites	Drug(s) in Program
		coremino
		DORYX
		DORYX MPC
		DOXYCYCLINE
		DOXYCYCLINE HYCLATE DR
		MINOCIN
		minocycline hydrochloride er
		MINOCYCLINE HYDROCHLORIDEER
		MINOLIRA
		ORACEA
		SEYSARA
		SOLODYN
		VIBRAMYCIN
		XIMINO
<b>PPI</b>	<b>A generic oral formulation of omeprazole, lansoprazole, pantoprazole, rabeprazole, esomeprazole magnesium</b>	ACIPHEX
		ACIPHEX SPRINKLE
		DEXILANT
		DEXLANSOPRAZOLE
		ESOMEPRAZOLE STRONTIUM
		NEXIUM
		omeprazole/sodium bicarbonate
		PREVACID
		PREVACID SOLUTAB
		PRILOSEC
		PROTONIX
		RABEPRAZOLE SODIUM DR SPRINKLE
		ZEGERID
<b>Rho Kinase Inhibitors</b>	<b>A generic ophthalmic prostaglandin</b>	RHOPRESSA
		ROCKLATAN
<b>SGLT-2 Inhibitors</b>	<b>ONE of the following: Glyxambi, Jardiance, Synjardy, Synjardy XR, Trijardy XR AND ONE of the following: Farxiga, Xigduo</b>	INVOKAMET
	<b>ONE of the following: Glyxambi, Jardiance, Synjardy, Synjardy XR, Trijardy XR AND ONE of the following: Farxiga, Xigduo</b>	INVOKAMET XR
	<b>ONE of the following: Glyxambi, Jardiance, Synjardy, Synjardy XR, Trijardy XR AND ONE of the following: Farxiga, Xigduo</b>	INVOKANA
	<b>Glyxambi, Trijardy XR</b>	QTERN
	<b>ONE of the following: Glyxambi, Jardiance, Synjardy, Synjardy XR, Trijardy XR</b>	SEGLUROMET

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Prerequisites	Drug(s) in Program
	<b>AND ONE of the following: Farxiga, Xigduo</b>	
	<b>ONE of the following: Glyxambi, Jardiance, Synjardy, Synjardy XR, Trijardy XR</b>	STEGLATRO
	<b>AND ONE of the following: Farxiga, Xigduo Glyxambi, Trijardy XR</b>	STEGLUJAN
<b>Statins</b>	<b>A generic statin or generic statin combination</b>	ALTOPREV
		CRESTOR
		EZALLOR SPRINKLE
		EZETIMIBE/ROSUVASTATIN
		FLOLIPID
		LESCOL XL
		LIPITOR
		LIVALO
		PRAVACHOL
		ROSZET
		SIMVASTATIN
		VYTORIN
		ZOCOR
		ZYPITAMAG
<b>Triptans</b>	<b>A generic triptan</b>	AMERGE
		FROVA
		IMITREX
		IMITREX STATDOSE REFILL
		IMITREX STATDOSE SYSTEM
		MAXALT
		MAXALT-MLT
		ONZETRA XSAIL
		RELPAX
		SUMATRIPTAN SUCCINATE
		SUMATRIPTAN SUCCINATE REFILL
		TOSYMRA
		TREXIMET
		ZEMBRACE SYMTOUCH
		ZOLMITRIPTAN
		ZOMIG
		ZOMIG ZMT
<b>Winlevi</b>	<b>A generic topical antibiotic agent, topical retinoid agent</b>	WINLEVI

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.